Öfugar hýdroxamat afleiður sem málmpróteasa latar
A family of compounds having general structural formula (I) wherein W is a reverse hydroxamic acid group (a); R5 is hydrogen or lower alkyl; R6 is (b); where Z1 is heteroarylene; preferably: R1 is methyl, ethyl, isopropyl, n-propyl or 3,3,3-trifluoro-n-propyl; R2 is isobutyl or sec-butyl; R3 is hydr...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | ice |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | JOSEPH HOWING CHAN DARRYL LYNN MCDOUGALD ROBERT WILLIAM WIETHE JENNIFER BADIANG STANFORD DAVID LEE MUSSO MICHAEL DAVID GAUL DULCIE GARRIDO BUBACZ DAVID JOHN COWAN MARC WERNER ANDERSEN MICHAEL HOWARD RABINOWITZ ROBERT CARL ANDREWS |
| description | A family of compounds having general structural formula (I) wherein W is a reverse hydroxamic acid group (a); R5 is hydrogen or lower alkyl; R6 is (b); where Z1 is heteroarylene; preferably: R1 is methyl, ethyl, isopropyl, n-propyl or 3,3,3-trifluoro-n-propyl; R2 is isobutyl or sec-butyl; R3 is hydrogen; R4 is tert-butyl, sec-butyl, 1-methoxy-1-ethyl or 2-(2-pyridylcarbonylamino)-1-ethyl; R5 is hydrogen; and R6 is 2-thiazolyl or 2-pyridyl. Such compounds show potent inhibition of MMP's, cell-free TNF convertase enzyme and TNF release from cells, and in some cases inhibit TNF convertase and TNF release from cells in preference to matrix metalloproteases. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_IS5159A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>IS5159A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_IS5159A3</originalsourceid><addsrcrecordid>eNrjZDA7PC2tND2xSCHj8N6UovyKxNzEEoXEtJzUzMMbSosUilNzFXIPL8zJLSg6vLkkNbE4USEnsSSxiIeBNS0xpziVF0pzM8i4uYY4e-imFuTHpxYXJCan5qWWxHsGmxqaWjoaE5AGAIDVL0s</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Öfugar hýdroxamat afleiður sem málmpróteasa latar</title><source>esp@cenet</source><creator>JOSEPH HOWING CHAN ; DARRYL LYNN MCDOUGALD ; ROBERT WILLIAM WIETHE ; JENNIFER BADIANG STANFORD ; DAVID LEE MUSSO ; MICHAEL DAVID GAUL ; DULCIE GARRIDO BUBACZ ; DAVID JOHN COWAN ; MARC WERNER ANDERSEN ; MICHAEL HOWARD RABINOWITZ ; ROBERT CARL ANDREWS</creator><creatorcontrib>JOSEPH HOWING CHAN ; DARRYL LYNN MCDOUGALD ; ROBERT WILLIAM WIETHE ; JENNIFER BADIANG STANFORD ; DAVID LEE MUSSO ; MICHAEL DAVID GAUL ; DULCIE GARRIDO BUBACZ ; DAVID JOHN COWAN ; MARC WERNER ANDERSEN ; MICHAEL HOWARD RABINOWITZ ; ROBERT CARL ANDREWS</creatorcontrib><description>A family of compounds having general structural formula (I) wherein W is a reverse hydroxamic acid group (a); R5 is hydrogen or lower alkyl; R6 is (b); where Z1 is heteroarylene; preferably: R1 is methyl, ethyl, isopropyl, n-propyl or 3,3,3-trifluoro-n-propyl; R2 is isobutyl or sec-butyl; R3 is hydrogen; R4 is tert-butyl, sec-butyl, 1-methoxy-1-ethyl or 2-(2-pyridylcarbonylamino)-1-ethyl; R5 is hydrogen; and R6 is 2-thiazolyl or 2-pyridyl. Such compounds show potent inhibition of MMP's, cell-free TNF convertase enzyme and TNF release from cells, and in some cases inhibit TNF convertase and TNF release from cells in preference to matrix metalloproteases.</description><language>ice</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>1999</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19990820&DB=EPODOC&CC=IS&NR=5159A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19990820&DB=EPODOC&CC=IS&NR=5159A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>JOSEPH HOWING CHAN</creatorcontrib><creatorcontrib>DARRYL LYNN MCDOUGALD</creatorcontrib><creatorcontrib>ROBERT WILLIAM WIETHE</creatorcontrib><creatorcontrib>JENNIFER BADIANG STANFORD</creatorcontrib><creatorcontrib>DAVID LEE MUSSO</creatorcontrib><creatorcontrib>MICHAEL DAVID GAUL</creatorcontrib><creatorcontrib>DULCIE GARRIDO BUBACZ</creatorcontrib><creatorcontrib>DAVID JOHN COWAN</creatorcontrib><creatorcontrib>MARC WERNER ANDERSEN</creatorcontrib><creatorcontrib>MICHAEL HOWARD RABINOWITZ</creatorcontrib><creatorcontrib>ROBERT CARL ANDREWS</creatorcontrib><title>Öfugar hýdroxamat afleiður sem málmpróteasa latar</title><description>A family of compounds having general structural formula (I) wherein W is a reverse hydroxamic acid group (a); R5 is hydrogen or lower alkyl; R6 is (b); where Z1 is heteroarylene; preferably: R1 is methyl, ethyl, isopropyl, n-propyl or 3,3,3-trifluoro-n-propyl; R2 is isobutyl or sec-butyl; R3 is hydrogen; R4 is tert-butyl, sec-butyl, 1-methoxy-1-ethyl or 2-(2-pyridylcarbonylamino)-1-ethyl; R5 is hydrogen; and R6 is 2-thiazolyl or 2-pyridyl. Such compounds show potent inhibition of MMP's, cell-free TNF convertase enzyme and TNF release from cells, and in some cases inhibit TNF convertase and TNF release from cells in preference to matrix metalloproteases.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>1999</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDA7PC2tND2xSCHj8N6UovyKxNzEEoXEtJzUzMMbSosUilNzFXIPL8zJLSg6vLkkNbE4USEnsSSxiIeBNS0xpziVF0pzM8i4uYY4e-imFuTHpxYXJCan5qWWxHsGmxqaWjoaE5AGAIDVL0s</recordid><startdate>19990820</startdate><enddate>19990820</enddate><creator>JOSEPH HOWING CHAN</creator><creator>DARRYL LYNN MCDOUGALD</creator><creator>ROBERT WILLIAM WIETHE</creator><creator>JENNIFER BADIANG STANFORD</creator><creator>DAVID LEE MUSSO</creator><creator>MICHAEL DAVID GAUL</creator><creator>DULCIE GARRIDO BUBACZ</creator><creator>DAVID JOHN COWAN</creator><creator>MARC WERNER ANDERSEN</creator><creator>MICHAEL HOWARD RABINOWITZ</creator><creator>ROBERT CARL ANDREWS</creator><scope>EVB</scope></search><sort><creationdate>19990820</creationdate><title>Öfugar hýdroxamat afleiður sem málmpróteasa latar</title><author>JOSEPH HOWING CHAN ; DARRYL LYNN MCDOUGALD ; ROBERT WILLIAM WIETHE ; JENNIFER BADIANG STANFORD ; DAVID LEE MUSSO ; MICHAEL DAVID GAUL ; DULCIE GARRIDO BUBACZ ; DAVID JOHN COWAN ; MARC WERNER ANDERSEN ; MICHAEL HOWARD RABINOWITZ ; ROBERT CARL ANDREWS</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_IS5159A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>ice</language><creationdate>1999</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>JOSEPH HOWING CHAN</creatorcontrib><creatorcontrib>DARRYL LYNN MCDOUGALD</creatorcontrib><creatorcontrib>ROBERT WILLIAM WIETHE</creatorcontrib><creatorcontrib>JENNIFER BADIANG STANFORD</creatorcontrib><creatorcontrib>DAVID LEE MUSSO</creatorcontrib><creatorcontrib>MICHAEL DAVID GAUL</creatorcontrib><creatorcontrib>DULCIE GARRIDO BUBACZ</creatorcontrib><creatorcontrib>DAVID JOHN COWAN</creatorcontrib><creatorcontrib>MARC WERNER ANDERSEN</creatorcontrib><creatorcontrib>MICHAEL HOWARD RABINOWITZ</creatorcontrib><creatorcontrib>ROBERT CARL ANDREWS</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>JOSEPH HOWING CHAN</au><au>DARRYL LYNN MCDOUGALD</au><au>ROBERT WILLIAM WIETHE</au><au>JENNIFER BADIANG STANFORD</au><au>DAVID LEE MUSSO</au><au>MICHAEL DAVID GAUL</au><au>DULCIE GARRIDO BUBACZ</au><au>DAVID JOHN COWAN</au><au>MARC WERNER ANDERSEN</au><au>MICHAEL HOWARD RABINOWITZ</au><au>ROBERT CARL ANDREWS</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Öfugar hýdroxamat afleiður sem málmpróteasa latar</title><date>1999-08-20</date><risdate>1999</risdate><abstract>A family of compounds having general structural formula (I) wherein W is a reverse hydroxamic acid group (a); R5 is hydrogen or lower alkyl; R6 is (b); where Z1 is heteroarylene; preferably: R1 is methyl, ethyl, isopropyl, n-propyl or 3,3,3-trifluoro-n-propyl; R2 is isobutyl or sec-butyl; R3 is hydrogen; R4 is tert-butyl, sec-butyl, 1-methoxy-1-ethyl or 2-(2-pyridylcarbonylamino)-1-ethyl; R5 is hydrogen; and R6 is 2-thiazolyl or 2-pyridyl. Such compounds show potent inhibition of MMP's, cell-free TNF convertase enzyme and TNF release from cells, and in some cases inhibit TNF convertase and TNF release from cells in preference to matrix metalloproteases.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | ice |
| recordid | cdi_epo_espacenet_IS5159A |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | Öfugar hýdroxamat afleiður sem málmpróteasa latar |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T08%3A57%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=JOSEPH%20HOWING%20CHAN&rft.date=1999-08-20&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EIS5159A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |